Clinical Trial Update: Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe) [Phase 1, Phase 2]

View source ↗

Summary

A double-blind Phase 1/2 trial evaluating rituximab given by intravenous and intrathecal injection versus placebo in low-inflammatory secondary progressive mult…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Multiple Sclerosis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-03-28